LUNELLE™ Monthly Contraceptive Injection contains medroxyprogesterone acetate and estradiol cypionate as its active ingredients.
LUNELLE™ Monthly Contraceptive Injection is indicated for the prevention of pregnancy.
The efficacy of LUNELLE™ Monthly Contraceptive Injection is dependent on adherence to the recommended dosage schedule (e.g., intramuscular injections every 28 to 30 days, not to exceed 33 days). To ensure that LUNELLE™ Monthly Contraceptive Injection is not administered inadvertently to a pregnant woman, the first injection should be given during the first 5 days of a normal menstrual period. LUNELLE™ Monthly Contraceptive Injection should be administered no earlier than 4 weeks after delivery if not breastfeeding or 6 weeks after delivery if breastfeeding (see NURSING MOTHERS).
Media Articles Related to Lunelle (Medroxyprogesterone / Estradiol)
Tell Patients When Religion Will Affect a Hospital's Care?
Source: Medscape Business of Medicine Headlines [2017.02.23]
Religious hospitals may not consent to abortion, contraception, infertility treatment, or physician-assisted dying where it is legal, and patients may not know it. Is it your job to inform them?
Medscape Business of Medicine
Male contraceptive proves effective as alternative to vasectomy
Source: Pregnancy / Obstetrics News From Medical News Today [2017.02.07]
A new trial in adult rhesus monkeys tests the effectiveness of Vasalgel - a non-hormonal gel developed as a long-term form of male contraception.
Published Studies Related to Lunelle (Medroxyprogesterone / Estradiol)
Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. [2011.03.01]
In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or natural E(2) gel (1.5 mg) with oral micronized P (200 mg) on 14 of the 28 days of each cycle.
Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. 
BACKGROUND/AIM: The aim of this prospective controlled study was to compare the effects of two therapies for menopause on factor VII (FVII) and hemostatic variables... CONCLUSION: Our results show that tibolone induces a significant reduction in FVIIc and Lp(a) and a greater enhancement of factors promoting fibrinolysis than the TTS E2/MPA regimen.
Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. [2008.05]
CONTEXT: Endothelial dysfunction in resistance arteries after menopause is important for the development of high blood pressure and cardiovascular disease. OBJECTIVES: Our objectives were to study the effects of different hormone replacement therapies on the function and morphology of isolated resistance arteries, and to look for their mechanistic basis... CONCLUSIONS: This study suggests that hormone replacement therapy with estrogens or in combination with MPA may benefit the function of resistance arteries and may preserve the morphological integrity of endothelial cells by regulatory actions on the cytoskeleton.
Synchronization of follicular wave emergence in the seasonally anestrous ewe: the effects of estradiol with or without medroxyprogesterone acetate. [2008.04.15]
Fertility is often lower in anestrous compared to cyclic ewes, after conventional estrus synchronization. We hypothesized that synchronization of ovarian follicular waves and ovulation could improve fertility at controlled breeding in anestrous ewes... All ewes given eCG ovulated 3-4d after injection; this predictable time of ovulation may be efficacious for AI and embryo transfer.
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women. [2008.04]
Medroxyprogesterone acetate (MPA) is widely known for its use in combination hormone therapy for postmenopausal women. However, MPA is also commonly used in young women for contraception and treatment of a number of gynecological conditions...
Clinical Trials Related to Lunelle (Medroxyprogesterone / Estradiol)
Pharmacokinetic and Pharmacodynamic Study of Cyclofem [Completed]
Cyclofem® is a monthly injectable contraceptive containing 25 mg of MPA and 5 mg of
estradiol cypionate (E2C), a long acting ester of estradiol. The current study will assess
the steady-state pharmacokinetics and pharmacodynamics of MPA and E2 after administration of
Cyclofem® and will provide critical information to determine similar bioavailability of
Cyclofem to Lunelle in women residing in the USA.